Findings

What do systematic reviews say?

154 questions · 163 findings · 21 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 18 · 11%GRADE not reported 2 · 1.2%Very low 27 · 16.6%Low 61 · 37.4%Moderate 51 · 31.3%High 4 · 2.5%

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Adverse events · Patients with collagenous colitis

Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 0.69 [0.43, 1.1]
1 study · 55 participants
Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Withdrawals due to adverse events · Patients with collagenous colitis

Budesonide showed no clear difference in withdrawals due to adverse events compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 0.09 [0.01, 1.65]
1 study · 55 participants
Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Clinical response · patients with active lymphocytic colitis

Budesonide may leads to higher clinical response compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
RR 2.03 [1.25, 3.33]
2 studies · 57 participants
Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Histological response · patients with active lymphocytic colitis

Budesonide may leads to higher histological response compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
RR 2.44 [1.13, 5.28]
2 studies · 39 participants
Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Adverse events · patients with active lymphocytic colitis

Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
RR 0.67 [0.12, 3.59]
1 study · 42 participants
Low

Budesonide vs placebo

Incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness

Budesonide may leads to lower incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival… compared with placebo (low certainty).

1 finding from 1 review

Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs 2017 · Cochrane Headline outcomes only
RR 0.37 [0.23, 0.61]
2 studies · 132 participants
Low

Budesonide vs placebo

Incidence of high altitude pulmonary oedema (HAPE)‐ not reported · participants at risk of high altitude illness

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Budesonide vs placebo

Incidence of high altitude cerebral oedema (HACE) ‐ not reported · participants at risk of high altitude illness

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Budesonide vs placebo

Side effects or other adverse events · participants at risk of high altitude illness

1 finding from 1 review

Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Budesonide 3 mg vs placebo

Clinical remission · Patients with active Crohn's disease

Budesonide 3 mg showed no clear difference in induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (low certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1.67 [0.92, 3.02]
1 study · 133 participants
Low

Budesonide 9 mg vs steroids

Clinical remission · Patients with active Crohn's disease

Budesonide 9 mg probably leads to lower induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with conventional steroids (moderate certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.85 [0.75, 0.97]
8 studies · 750 participants
Moderate

Budesonide 9 mg vs steroids

Withdrawals due to adverse events · Patients with active Crohn's disease

Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.57 [0.18, 1.84]
5 studies · 522 participants
Low

Budesonide 9 mg vs steroids

Withdrawal due to disease worsening · Patients with active Crohn's disease

It is very uncertain whether budesonide 9 mg changes withdrawal due to disease worsening compared with conventional steroids (very low certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1 [0.07, 14.55]
1 study · 30 participants
Very low

Budesonide 9 mg vs mesalamine

Clinical remission · Patients with active Crohn's disease

Budesonide 9 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeksThomsen 1998 compared with mesalamine (moderate certainty).

2 findings from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1.63 [1.23, 2.16]
1 study · 182 participants
Moderate
Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1.12 [0.95, 1.32]
1 study · 307 participants
Moderate

Budesonide 3 mg vs placebo

Withdrawals due to adverse events · Patients with active Crohn's disease

Budesonide 3 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.66 [0.11, 3.8]
1 study · 133 participants
Low

Budesonide 9 mg vs mesalamine

Clinical improvement (decrease in CDAI > 100 or total CDAI < 150) · Patients with active Crohn's disease

Budesonide 9 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI < 150) compared with mesalamine (moderate certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1.18 [0.99, 1.42]
2 studies · 489 participants
Moderate

Budesonide 9 mg vs mesalamine

Withdrawals due to adverse events · Patients with active Crohn's disease

Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with mesalamine (low certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.43 [0.18, 1.03]
2 studies · 489 participants
Low

Budesonide 9 mg vs mesalamine

Withdrawal due to disease worsening · Patients with active Crohn's disease

Budesonide 9 mg probably leads to lower withdrawal due to disease worsening compared with mesalamine (moderate certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.35 [0.18, 0.69]
1 study · 182 participants
Moderate

Budesonide 3 mg vs placebo

Withdrawal due to disease worsening · Patients with active Crohn's disease

Budesonide 3 mg showed no clear difference in withdrawal due to disease worsening compared with placebo (moderate certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.92 [0.64, 1.33]
1 study · 133 participants
Moderate

Budesonide 3 mg vs placebo

Corticosteroid related adverse events · Patients with active Crohn's disease

Budesonide 3 mg showed no clear difference in corticosteroid related adverse events compared with placebo (low certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.58 [0.29, 1.17]
1 study · 133 participants
Low